ImmuCell Corporation Lessee, Operating Lease, Liability, to be Paid, Year One
ImmuCell Corporation (ICCC) had Lessee, Operating Lease, Liability, to be Paid, Year One of $346.87 thousand as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-30
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $346.87K.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $346.87K.
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $346.87K.
- 2025-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $349.74K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $346.87K 10-K · filed 2026-03-30 |
| 2025-09-30 | $346.87K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $346.87K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $349.74K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $711.62K 10-K · filed 2025-03-28 |
| 2024-09-30 | $711.62K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $711.62K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $342.88K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $946.00K 10-K · filed 2024-04-01 |
| 2023-09-30 | $337.26K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $154.06K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |